Inclusion Criteria:

- Histologically/cytologically proven prostate adenocarcinoma

- Progression or non response with previous chemotherapy regimen (excluding Taxotere®)

- Received previous mitoxantrone/prednisone or one other chemotherapy regimen including
emcyt +/- vinblastine

- Castration levels of testosterone (<50 ng/dL )

- ECOG performance status 0-2

- Laboratory requirements :

1. Hematology:

- Neutrophils ≥ 1.5 x 10^9/L

- Hemoglobin > 10 g/dL (prior transfusion permitted).

- Platelets ≥ 100 x 10^9/L

2. Hepatic function:

- Total bilirubin < the upper-normal limit of the institution.

- ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the upper-normal limit of the
institution.

3. Renal function:

- Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1)

- No severe or uncontrolled disease

Exclusion Criteria

- Chemotherapy within the last 4 weeks

- Anti-androgen therapy within the last 4 weeks.

- Prior malignancy except the following: adequately treated non-melanomatous skin
cancer and superficial bladder cancer from which the patient has been disease-free
for >2 years.

- Concurrent treatment with other experimental drugs. Participation in another clinical
trial with any investigational drug within 30 days prior to study screening.

- Treatment with any other anti-cancer therapy (except LHRH agonists) including any
prescribed compounds and/or OTC products for the treatment of prostate cancer must be
stopped prior to study entry.

- Other serious illness, psychiatric or medical condition that would not permit the
patient to be managed according to the protocol including active uncontrolled
infection and significant cardiac dysfunction.